15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Effect of microRNA-21 on multidrug resistance reversal in A549/DDP human lung cancer cells.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Lung cancer is a predominant cause of cancer-related mortality and numerous lung cancer patients succumb to the disease due to drug resistance. A number of microRNAs (miRNAs) are upregulated in cancer and are involved in tumorigenesis, functioning as oncogenes. Several functional studies have shown that miR-21 is important in carcinogenesis; however, none of these studies has investigated multidrug resistance (MDR) reversal in human lung cancer cells. In the present study, the effect of miR-21 on MDR reversal was analyzed in A549/DDP lung cancer cells. The data demonstrated the following after miR-21 silencing: Proliferation of the tumor cells was inhibited, cell apoptosis and oxidative damage were increased, the cell cycle was blocked at the G0/G1 phase, expression levels of P-glycoprotein were reduced, accumulation of Rhodamine 123 was increased, and the MDR-related genes encoding MDR1, MPR, glutathione S-transferase-π, B-cell lymphoma 2, cyclin-dependent kinase 1, cystathione and glutathione were downregulated. Further mechanistic analysis revealed that miR-21 silencing reduced AKT phosphorylation and transcriptional activation of E2F-1 and Twist. In conclusion, this study demonstrated that miR-21 silencing reversed lung cancer cell MDR by modulation of MDR-related gene expression and inhibition of the AKT signaling pathway, suggesting that miR-21 may be a potential therapeutic candidate in patients with MDR lung cancer.

          Related collections

          Author and article information

          Journal
          Mol Med Rep
          Molecular medicine reports
          Spandidos Publications
          1791-3004
          1791-2997
          Jan 2015
          : 11
          : 1
          Affiliations
          [1 ] Department of Clinical Laboratory, Tianjin Medical University General Hospital, Heping District, Tianjin 300052, P.R. China.
          [2 ] Department of Clinical Laboratory, Key Laboratory of Cancer Prevention and Therapy, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Hexi 300060, P.R. China.
          [3 ] Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Hexi 300060, P.R. China.
          Article
          10.3892/mmr.2014.2662
          25323306
          d6d7657e-f78d-4d1c-acb4-12b6dc47fdb5
          History

          Comments

          Comment on this article